Cartesian Therapeutics (RNAC) Fundamental Analysis: Revenue, Earnings & Valuation

5.23 / 10

Netural

The stock displays modest fundamental strength (5.2/10). Encouraging metrics: Asset-MV and Cash-MV, balanced by issues in Revenue-MV and Current assets turnover ratio. This profile warrants a moderate stance.

Analysis Checks(6/10)

Revenue-MV

Value-3.59

Score1/3

Weight9.21%

1M Return3.35%

Total operating revenue (YoY growth rate %)

Value-92.81

Score2/3

Weight-3.32%

1M Return-1.27%

Inventory turnover ratio

Value98.02

Score3/3

Weight19.68%

1M Return5.85%

Gross profit margin (%)

Value100.00

Score2/3

Weight5.02%

1M Return1.63%

Income tax / Total profit (%)

Value6.59

Score1/3

Weight-0.82%

1M Return-0.31%

Current assets turnover ratio

Value0.02

Score0/3

Weight-6.73%

1M Return-2.59%

Fixed assets turnover ratio

Value0.25

Score1/3

Weight-6.21%

1M Return-2.42%

Cost of sales ratio (%)

Value71.87

Score3/3

Weight13.96%

1M Return4.48%

Asset-MV

Value-0.49

Score2/3

Weight53.53%

1M Return14.72%

Cash-MV

Value0.01

Score2/3

Weight15.69%

1M Return4.74%

Is RNAC undervalued or overvalued?

RNAC scores 5.23/10 on fundamentals and holds a Fair valuation at present. Backed by its 0.00% ROE, -4658.63% net margin, -1.27 P/E ratio, -1.31 P/B ratio, and -12.05% earnings growth, these metrics solidify its Netural investment rating.